TCRX Company Profile and Key Details

TScan Therapeutics, Inc. (NASDAQ:TCRX) closed at $0.91 USD, losing -$0.05 (-5.30%) from the previous close of $0.96. The stock is currently within 5% of its 52-week low $0.88 and $2.57. With a market capitalization of about $51.66 million, TScan Therapeutics, Inc. is classified as a micro-cap and shows market-like volatility (beta ~1.04). Key stats such as the average daily volume over the past year has been around 669.19 thousand shares, in line with its 52-week average. Headquartered in Waltham, MA, TScan Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Gavin MacBeath, the company employs approximately 200 people and listed since July 16, 2021. TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer.

Short-term trend indicators are mixed aligned (SMA20 -17.38%, SMA50 -13.35%, SMA200 -40.16%). The stock’s 14-day RSI is 29.92 (weak momentum), while the ATR of 0.07 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -64.58% below its high and over 3.17% above its low. Average 10-day trading volume of 479.94 thousand shares is below the 3-month average of 667.22 thousand, indicating normal recent market interest.

TScan Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$1.58. This means the shares are trading below this model’s fair value.

TScan Therapeutics, Inc. generated EPS of -$1.12 over the past year. Five-year average earnings growth is -14.41%. Wall Street analysts project EPS growth of 9.18% annually over the next five years. The latest quarter delivered EPS of -$0.28. The next quarter is forecast at -$0.27. Next year's EPS is expected at $21.90. Analyst sentiment is bullish. Analyst rating data shows there are 2 Strong Buy ratings, 5 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $15.00 to $3.00. The high target offers 1548.35% upside. The low target suggests 229.67% downside. The mean target is $8.43. This offers 826.37% upside. TScan Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended November 12, 2025, missed forecasts by -21.42%. The prior quarter beat by 0.0%. Over the last six quarters, Apple has recorded several small beats. These include -6.67% in August 12, 2024.

TScan Therapeutics, Inc. has 52.47 million shares outstanding. The public float is 44.03 million shares, elevated short interest at 3.97% of float. This equals 1.85 million shares. The short ratio is 6.82 days. Institutional investors hold 73.5% of the float. Insiders own 0.23%. Lynx1 Capital Management LP holds 8.02 million shares, BAKER BROS. ADVISORS LP has 4.02 million shares and Baker Brothers Life Sciences LP has 2.53 million shares. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.